ABIONYX Pharma Announces Its Financial Agenda for the Year 2022
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2022.
| Events
|
Date*
|
| Cash position and activity update for Q4 2021
|
February 24, 2022
|
| 2021 Annual Results
|
April 28, 2022
|
| Cash position and activity update for Q1 2022
|
May 19, 2022
|
| Cash position and activity update for Q2 2022
|
August 18, 2022
|
| 2022 Half Year Results
|
September 29, 2022
|
| Cash position and activity update for Q3 2022
|
November 17, 2022
|
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005656/en/
NewCap
Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53
NewCap
Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98
